Comparisons
Retatrutide vs Semaglutide: One Receptor or Three
Semaglutide is a selective GLP-1 receptor agonist; retatrutide activates GIP, GLP-1 and glucagon receptors. Structure, half-life and trial endpoints compared.
Side-by-side reviews of related compounds: how they differ in structure, receptor targets, half-life and the evidence behind them.
Comparisons
Semaglutide is a selective GLP-1 receptor agonist; retatrutide activates GIP, GLP-1 and glucagon receptors. Structure, half-life and trial endpoints compared.
Comparisons
Retatrutide adds glucagon receptor activity to tirzepatide's GIP/GLP-1 agonism. Receptors, half-life, status and trial endpoints compared.
Comparisons
Semax and Selank share a Pro-Gly-Pro tail but come from different parent peptides. How their structures, mechanisms and published research differ.
Comparisons
Tesamorelin activates the GHRH receptor; ipamorelin activates the ghrelin receptor. Structure, pharmacology, evidence base and why they are studied together.
Comparisons
Sermorelin is GHRH(1-29)-NH2; tesamorelin is full-length GHRH(1-44) with an N-terminal hexenoyl group. Structure, stability and clinical history compared.
Comparisons
BPC-157 and TB-500 are often grouped together but differ in origin, size and pathway. A side-by-side comparison of structure, mechanisms and published evidence.
Comparisons
DAC (drug affinity complex) lets CJC-1295 bind albumin, turning a short-acting GHRH analogue into one with a ~1-week half-life. How the two forms differ.
Comparisons
N-acetyl Selank amidate caps the Selank heptapeptide at both ends. How the modifications affect mass, charge and degradation, and what the evidence supports.
Comparisons
N-acetyl Semax amidate caps both ends of the Semax heptapeptide. What acetylation and amidation change, how masses differ, and what the literature supports.
Comparisons
NAD, NAD+ and NADH are the same coenzyme in different states. What the plus sign means, which form is oxidised, and why the ratio matters in the lab.